ALIF B Stock Overview
Provides equipment, consumables, and reagents primarily to healthcare sector, research, colleges, and universities, as well as the food and pharmaceutical industries.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 4/6 |
Past Performance | 2/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
AddLife AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr124.50 |
52 Week High | kr130.10 |
52 Week Low | kr54.75 |
Beta | 1.25 |
1 Month Change | 8.07% |
3 Month Change | 19.25% |
1 Year Change | 2.13% |
3 Year Change | -48.04% |
5 Year Change | 72.92% |
Change since IPO | 352.73% |
Recent News & Updates
Recent updates
Revenues Working Against AddLife AB (publ)'s (STO:ALIF B) Share Price
May 29Are Investors Undervaluing AddLife AB (publ) (STO:ALIF B) By 42%?
Apr 22Is It Time To Consider Buying AddLife AB (publ) (STO:ALIF B)?
Apr 06AddLife AB (publ) Just Missed Earnings - But Analysts Have Updated Their Models
Feb 07AddLife AB (publ)'s (STO:ALIF B) 28% Share Price Surge Not Quite Adding Up
Dec 19AddLife (STO:ALIF B) Has A Somewhat Strained Balance Sheet
Dec 09Is It Too Late To Consider Buying AddLife AB (publ) (STO:ALIF B)?
Nov 21Is There An Opportunity With AddLife AB (publ)'s (STO:ALIF B) 43% Undervaluation?
Oct 14AddLife (STO:ALIF B) Has A Somewhat Strained Balance Sheet
Sep 08Is Now The Time To Look At Buying AddLife AB (publ) (STO:ALIF B)?
Aug 18Calculating The Fair Value Of AddLife AB (publ) (STO:ALIF B)
Jul 05Is Now An Opportune Moment To Examine AddLife AB (publ) (STO:ALIF B)?
May 18Is AddLife (STO:ALIF B) Using Too Much Debt?
Apr 28AddLife (STO:ALIF B) Is Paying Out Less In Dividends Than Last Year
Apr 05AddLife (STO:ALIF B) Is Paying Out Less In Dividends Than Last Year
Feb 21AddLife (STO:ALIF B) Has Announced That Its Dividend Will Be Reduced To SEK1.20
Feb 07Should You Think About Buying AddLife AB (publ) (STO:ALIF B) Now?
Jan 20AddLife (STO:ALIF B) Has A Pretty Healthy Balance Sheet
Dec 30Calculating The Fair Value Of AddLife AB (publ) (STO:ALIF B)
Oct 27Should You Think About Buying AddLife AB (publ) (STO:ALIF B) Now?
Oct 11Is AddLife (STO:ALIF B) A Risky Investment?
Sep 23When Should You Buy AddLife AB (publ) (STO:ALIF B)?
Jul 11Is AddLife (STO:ALIF B) Using Too Much Debt?
Jun 25A Look At The Fair Value Of AddLife AB (publ) (STO:ALIF B)
Jun 05AddLife's (STO:ALIF B) Dividend Will Be Increased To kr2.00
May 02AddLife's (STO:ALIF B) Dividend Will Be Increased To kr2.00
Apr 17Shareholder Returns
ALIF B | SE Life Sciences | SE Market | |
---|---|---|---|
7D | 3.0% | -1.3% | -1.5% |
1Y | 2.1% | 15.0% | 12.9% |
Return vs Industry: ALIF B underperformed the Swedish Life Sciences industry which returned 15% over the past year.
Return vs Market: ALIF B underperformed the Swedish Market which returned 12.9% over the past year.
Price Volatility
ALIF B volatility | |
---|---|
ALIF B Average Weekly Movement | 5.5% |
Life Sciences Industry Average Movement | 5.6% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.7% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: ALIF B has not had significant price volatility in the past 3 months.
Volatility Over Time: ALIF B's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1906 | 2,289 | Fredrik Dalborg | www.add.life |
AddLife AB (publ), together with its subsidiaries, provides equipment, consumables, and reagents primarily to healthcare sector, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates through Labtech and Medtech segments. The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for plastic consumables, cell biology, reagents, lab, and other instruments.
AddLife AB (publ) Fundamentals Summary
ALIF B fundamental statistics | |
---|---|
Market cap | kr15.17b |
Earnings (TTM) | kr78.00m |
Revenue (TTM) | kr9.80b |
194.5x
P/E Ratio1.5x
P/S RatioIs ALIF B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALIF B income statement (TTM) | |
---|---|
Revenue | kr9.80b |
Cost of Revenue | kr6.16b |
Gross Profit | kr3.64b |
Other Expenses | kr3.56b |
Earnings | kr78.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 15, 2024
Earnings per share (EPS) | 0.64 |
Gross Margin | 37.17% |
Net Profit Margin | 0.80% |
Debt/Equity Ratio | 95.9% |
How did ALIF B perform over the long term?
See historical performance and comparison